Does David H. “Orac” Gorski, M.D., Ph.D, really CARE about Breast Cancer patients?

Dr. Gorski (@gorskon @OracKnows @ScienceBasedMed
http://www.scienceblogs.com/Insolence
#ScienceBasedMedicine
http://www.sciencebasedmedicine.org)
is advertised as being a “Breast Cancer Specialist”

The question is, does he really CARE about Breast Cancer patients?

2000-2001, clinical studies were conducted on breast cancer patients in Egypt, using antineoplaston A10
======================================
Burzynski: Egypt antineoplaston publications:
——————————————————————
https://stanislawrajmundburzynski.wordpress.com/2013/04/25/burzynski-egypt-antineoplaston-publication/
======================================
7/3/2000 they noted:
——————————————————————
Antineoplastons first described by Burzynski are naturally occurring peptides and amino acid derivatives, which control neoplastic growth
——————————————————————
Antineoplaston A-10 level measured in urine of:
31 breast cancer patients
17 normal women
——————————————————————
Significantly lower antineoplaston A-10 levels detected among patients with breast cancer
——————————————————————
Data suggest strong inverse association of urinary antineoplaston A-10 level with breast cancer
——————————————————————
Potential utility of antineoplaston A-10 as predictive test for women at risk of developing breast cancer
======================================
8/31/2000 they noted:
—————————————————————
Antineoplastons are naturally occurring cytodifferentiating agents
—————————————————————
Chemically, they are medium and small sized peptides, amino acid derivatives and organic acids, which exist in blood, tissues and urine
—————————————————————
Findings confirm presence of immune defects among patients with breast cancer and results should stimulate development of new strategies to induce and augment immunity for treatment of breast cancer
—————————————————————
Antineoplaston A-10 may provide rational basis for designing trials to employ its immune modulatory potentials as adjuvant therapy in breast cancer patients
======================================
12/2000 they noted:
—————————————————————
4 new piperidinedione A10 analogs synthesized and tested for antimitotic activity on human breast cancer cell line against prototype A10 and antibreast cancer drug tamoxifen
—————————————————————
DNA binding capacity of compounds evaluated against A10
—————————————————————
“3A” and “3C” had weaker biological profiles than lead compound A10
—————————————————————
“3B” and “3D” were several-fold more potent antiproliferative agents than A10 and tamoxifen and had significantly higher capacity to bind DNA than A10
======================================
10/1/2001 they noted:
—————————————————————
Reports on structural characterization of new antineoplaston (ANP) representatives
—————————————————————
Combination heat with pH modification had virtually no effect on obtained peaks, attesting to stability and purity of compounds
—————————————————————
One had superior affinity to DNA than prototype ANP-A10
======================================
8/2005 Antineoplastons such as A10 include naturally occurring peptides and amino acid derivatives that CONTROL NEOPLASTIC GROWTH OF CELLS
——————————————————————
Findings indicate antineoplaston A10 ANTITUMOR EFFECT could be utilized as effective therapy for breast cancer patients
——————————————————————
Antineoplaston induces G1 arrest by PKCα and MAPK pathway in SKBR-3 breast cancer cells
Hideaki H TSUDA Antineoplaston A10
http://www.ncbi.nlm.nih.gov/pubmed/16012735
Antineoplaston induces G1 arrest by PKCo and MAPK pathway in SKBR-3 breast cancer cells
http://www.ncbi.nlm.nih.gov/m/pubmed/16012735
Antineoplaston induces G(1) arrest by PKCalpha and MAPK pathway in SKBR-3 breast cancer cells
http://www.spandidos-publications.com/or/14/2/489
Oncol Rep. 8/2005; 14(2):489-94
http://gyouseki.kurume-u.ac.jp/PDF/ichiran_2005.pdf
Oncol Rep 14(2):489-94 (2005)
http://research.kurume-u.ac.jp/K90RES.php?scode=49485632873864
Oncol Rep. 2005; 14:489–94
http://onlinelibrary.wiley.com/doi/10.1002/iub.574/abstract
Oncol. Rep. 14, 489–494
http://onlinelibrary.wiley.com/doi/10.1002/iub.574/full
Oncology Reports, 8/2005, Volume 14 Number 2
Pages: 489-494
http://onlinelibrary.wiley.com/store/10.1002/iub.574/asset/574_ftp.pdf?v=1&t=hbr9z60q&s=0b1c1e8655db9c54b45dbf72062e8b11cb7895ac
Oncology Reports, Spandidos Publications
Department of Surgery, Kurume University School of Medicine, Kurume, Fukuoka, Japan
======================================
� � � � � � � � � � � � � � � �
1/2008 Novel mechanism through which all-trans retinoic acid (ATRA) and antineoplaston, ANTICANCER DRUG, CAUSED CELL GROWTH INHIBITION IN BREAST CANCER CELLS through effects on intracellular pathways
——————————————————————
Antineoplaston caused down-regulation of PKCalpha protein expression, resulting in INHIBITION of ERK MAPK phosphorylation, with resultant INHIBITION of Rb phosphorylation leading to G(1) arrest

Preclinical studies of molecular-targeting diagnostic and therapeutic strategies against breast cancer
http://www.ncbi.nlm.nih.gov/pubmed/18224398
antineoplaston
http://www.ncbi.nlm.nih.gov/m/pubmed/18224398
Breast Cancer 15(1):73-8 (2008)
DOI: 10.1007/s12282-007-0015-y
http://link.springer.com/article/10.1007%2Fs12282-007-0015-y
15(1):73-8
http://www.springerlink.com/content/p724x34746l56v73
Department of Surgery, Kurume University, Fukuoka, Japan
http://ci.nii.ac.jp/naid/10021288533
======================================
Burzynski has made it clear that:

… antineoplaston A10 rather than antineoplaston AS2-1 is main active drug
—————————————————————
Pg. 99
—————————————————————
http://www.burzynskiclinic.com/images/stories/Publications/960.pdf
—————————————————————
Burzynski has been using the “Parent” generation of antineoplastons in the phase II clinical trials, and could NOT just switch to new antineoplaston analogs which may produce better results

Also, Burzynski has made it clear that successive generations of antineoplastons have been developed which may also produce better results
—————————————————————
To those who seemed to think Burzynski’s phase II clinical trials were taking too long, he was following science based medicine’s:
—————————————————————
Pg. 94
—————————————————————
2-stage phase II clinical trial design proposed by Fleming [3]
—————————————————————
Pg. 100 References
—————————————————————
3. Fleming TR. One-sample multiple testing procedure for phase II clinical trials. Biometrics 1982; 38: 143-51
http://www.ncbi.nlm.nih.gov/pubmed/7082756/
Biometrics. 1982 Mar;38(1):143-51
http://www.ncbi.nlm.nih.gov/m/pubmed/7082756/
Biometrics Vol. 38, No. 1, Mar., 1982
http://www.jstor.org/discover/10.2307/2530297?uid=3739656&uid=2460338175&uid=2460337855&uid=2&uid=4&uid=83&uid=63&uid=3739256&sid=21102549294733
—————————————————————
To those who have made ridiculous statements to the effect that Burzynski is a murderer, and ignore that he has dealt with patients whom science based medicine’s chemotherapy therapy and / or radiation therapy did NOT work, what’s the difference when science based medicine fails?
——————————————————————
33 / 100% – DIED OF DISEASE PROGRESSION
——————————————————————
2004 – Supratentorial high-grade ASTROCYTOMA and DIFFUSE BRAINSTEM GLIOMA:
——————————————————————
two challenges for the pediatric oncologist
http://www.ncbi.nlm.nih.gov/pubmed/15047924/
Oncologist. 2004;9(2):197-206
http://www.ncbi.nlm.nih.gov/m/pubmed/15047924/
Oncologist 9, 197-206
http://m.theoncologist.alphamedpress.org/content/9/2/197.long
Division of Neuro-Oncology, Department of Hematology-Oncology, St. Jude Children’s Research Hospital, Memphis, Tennessee, USA
======================================
David James (@StortSkeptic) tweeted at 7:08pm – 1 Aug 13:

The new Doctor Who will be Stanislaw #Burzynski. He manages to continually avoid getting cornered and he gets away with murder.

—————————————————
To those who say that antineoplastons are toxic, what is the difference with science based medicine’s chemotherapy therapy or radiation therapy when we know that NOT all patients will experience all possible side-effects of a drug?

The successive generations of antineoplastons may be even better and have less potential side-effects
=====================================
10/1/2010 As degradation product of Antineoplaston A10 in vivo, PHENYLACETYL GLUTAMINE showed ANTITUMOR ACTIVITIES
——————————————————————
Designed and radiosynthesized PHENYLACETYL GLUTAMINE derivative, achieved under mild reaction condition
——————————————————————
radiochemical purity of (S)-2-((S)-2-(4-(3-fluoropropyl)benzamido)-3-phenylpropanamido)pentanedioic acid ([18F]FBPPA) was 98%, and best radiochemical yield was up to 46%
——————————————————————
results revealed it might become potential PET imaging agent for DETECTING TUMORS
——————————————————————
Antineoplaston A10 phenylacetyl glutamine (PG) – (S)-2-((S)-2-(4-(3-[18F]fluoropropyl)benzamido)-3-phenylpropanamido)pentanedioic acid labeled with 18F
http://www.springerlink.com/content/tj0177485773007t
(S)-2-((S)-2-(4-(3-[18 F] fluoropropyl) benzamido)-3-phenylpropanamido) pentanedioic acid labeled with 18 F
http://link.springer.com/article/10.1007%2Fs10967-010-0633-2?LI=true
Journal of Radioanalytical and Nuclear Chemistry, 2010, 286, 1, 135
http://www.springerlink.com/content/tj0177485773007t
October 2010, Volume 286, Issue 1, pp 135-140
http://link.springer.com/article/10.1007%2Fs10967-010-0633-2
DOI
10.1007/s10967-010-0633-2
http://link.springer.com/article/10.1007/s10967-010-0633-2/fulltext.html
Burzynski References: 5. – 6.
http://onlinelibrary.wiley.com/doi/10.1021/js960120y/abstract

http://www.springerlink.com/content/tj0177485773007t
======================================
Antineoplastons as a blood or urine “cancer test”:
—————————————————————
https://stanislawrajmundburzynski.wordpress.com/2013/02/22/antineoplastons-as-a-blood-or-urine-cancer-test/
======================================

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s